Literature DB >> 2205700

Hyperlipoproteinemia type I in a patient with active lipoprotein lipase in adipose tissue and indications of defective transport of the enzyme.

G Fager1, H Semb, S Enerbäck, T Olivecrona, L Jonasson, G Bengtsson-Olivecrona, G Camejo, G Bjursell, G Bondjers.   

Abstract

This paper presents a case of typical hyperlipoproteinemia type I in a young woman. Her serum triglycerides varied between 2 and 90 mmol/l and she had substantial amounts of apolipoprotein B-48 in fasting plasma. She had no detectable lipoprotein lipase (LPL) activity in post-heparin plasma (less than 0.2 percent of normal). Southern blot analysis suggested no major defect in her LPL gene and Northern blot analysis of adipose tissue RNA showed normal-sized LPL-mRNA. A 2-h [35S]methionine incorporation experiment with adipose tissue pieces in vitro showed that she produced normal-sized LPL and had LPL catalytic activity in the tissue. The amounts were, however, only 5-10% of control. No detectable LPL radioactivity or catalytic activity was released from patient tissue even in the presence of heparin in the incubations. Immunofluorescent staining of adipose tissue biopsies from the patient showed LPL immunoreactivity only in adipocytes and little or none within the capillaries. Treatment of immunoprecipitated labeled LPL with endoglycosidase H showed that the oligosaccharide chains on her enzyme were of the high-mannose type and not processed as in controls. Taken together the data suggest that the patient synthesizes a relatively normal LPL protein which is core-glycosylated and folded into active enzyme as in normal subjects, but is not effectively transported via the Golgi to the cell surface.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2205700

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  2 in total

Review 1.  Regulation of the synthesis, processing and translocation of lipoprotein lipase.

Authors:  J E Braun; D L Severson
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

2.  Tumor suppressor ZHX2 inhibits NAFLD-HCC progression via blocking LPL-mediated lipid uptake.

Authors:  Zhuanchang Wu; Hongxin Ma; Liyuan Wang; Xiaojia Song; Jie Zhang; Wen Liu; Yutong Ge; Yang Sun; Xiangguo Yu; Zehua Wang; Jianping Wang; Yankun Zhang; Chunyang Li; Nailin Li; Lifen Gao; Xiaohong Liang; Xuetian Yue; Chunhong Ma
Journal:  Cell Death Differ       Date:  2019-11-18       Impact factor: 15.828

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.